Defunct Company
Total Trials
6
As Lead Sponsor
As Collaborator
0
Total Enrollment
773
NCT06522048
SJS/TEN or Other Cutaneous Adverse Eevents Induced by Immune Checkpoint Inhibitors (ICIs) vs. Non-ICIs
Phase: N/A
Role: Lead Sponsor
Start: Jan 31, 2015
Completion: May 31, 2024
NCT06391996
Biologic Therapy for Generalized Pustular Psoriasis
Start: Jul 1, 2019
Completion: Dec 30, 2023
NCT06561256
JAK Inhibitors' Efficacy in Bullous Pemphigoid
Start: Jan 1, 2022
Completion: Jul 31, 2024
NCT06654817
Efficacy and Safety Evaluation of Anti-CD20 Monoclonal Antibody Combined with Azathioprine and Corticosteroids in the Treatment of Pemphigus Vulgaris
Start: Jan 1, 2023
Completion: Apr 1, 2024
NCT06686082
A Real-World Study of Biologic Therapy for Subclinical Psoriatic Arthritis
Start: Nov 1, 2023
Completion: Mar 25, 2025
NCT06663943
A Randomized Study on Pemphigus Treatment With Humanized CD38 Antibody CM313.
Phase: Phase 1/2
Start: Oct 1, 2025
Completion: Nov 1, 2026